<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AZTREONAM</span><br/>(az-tree'oh-nam)<br/><span class="topboxtradename">Azactam<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span><br/><b>Prototype: </b>Imipenem-Cilastatin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 1 g, 2 g vials</p>
<h1><a name="action">Actions</a></h1>
<p>Differs structurally from other beta-lactam antibiotics (penicillins and cephalosporins) in having a monocyclic rather than
         a bicyclic nucleus. Acts by inhibiting synthesis of bacterial cell wall, primarily in aerobic, gram-negative bacteria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Highly resistant to beta-lactamases and does not readily induce their formation. Spectrum of activity limited to aerobic,
         gram-negative bacteria. Therapeutically active against <i>Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae,</i> and against <i>Enterobacteriaceae</i> including most strains of <i>Escherichia coli, Enterobacter, Klebsiella, Proteus, Providencia, Shigella, Salmonella,</i> and <i>Serratia</i>. There appears to be little cross-allergenicity with penicillins and cephalosporins.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Gram-negative infections of urinary tract, lower respiratory tract, skin and skin structures; and for intraabdominal and gynecologic
         infections, septicemia, and as adjunctive therapy for surgical infections. Often used in combination with other antibiotics
         active against gram-positive and anaerobic bacteria in mixed infections.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety during pregnancy (category B), lactation, or in infants and children is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of hypersensitivity reaction to penicillin, cephalosporins, or to other drugs; impaired renal or hepatic function.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 0.51 g q812h<br/><br/><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g q68h (max: 8 g/24 h)<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV/IM</span>
<i><img src="../images/special/lesserorequal.gif"/>7 d</i>, 6090 mg/kg/d divided q812h; &gt;<i>7 d</i>, 60120 mg/kg/d divided q612h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> &gt;<i>1 mo</i>, 90120 mg/kg/d divided q68h<br/><br/><span class="indicationtitle">Cystic Fibrosis</span><br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 50 mg/kg q68h (max: 8 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute with at least 3 mL of diluent per gram of drug for IM injection. Immediately and vigorously shake vial to dissolve.
            Suitable diluents include sterile water for injection; bacteriostatic water for injection (with benzyl alcohol and propyl
            parabens); NS 0.9% for injection.
         </li>
<li>Give IM injections deeply into large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral thigh.
            Rotate injection sites.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p>Verify correct IV concentration and rate of infusion/injection with physician before giving to neonates, infants, and children.</p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct:</span>   Reconstitute a single dose with 610 mL of sterile water for injection.  Immediately shake vial until solution is dissolved. Reconstituted solutions are colorless to light straw yellow and turn slightly pink on standing. <span class="methodtype">Intermittent:</span> Each gram of reconstituted aztreonam must be further diluted in at least 50 mL of D5W, NS, or other solution approved by manufacturer
                  to yield a concentration not to exceed 20 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 35 min.  <span class="methodtype">Intermittent:</span> Give over 2060 min through Y-site.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Ampicillin,</b>
<b>metronidazole,</b>
<b>nafcillin.</b>
<span class="incompattype">Y-site:</span>
<b>Azithromycin.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Hypersensitivity (urticaria, eosinophilia, <span class="speceff-life">anaphylaxis</span>). <span class="typehead">CNS:</span> Headache, dizziness, confusion, paresthesias, insomnia, seizures. <span class="typehead">GI:</span> Nausea, <span class="speceff-common">diarrhea,</span> vomiting, elevated liver function tests. <span class="typehead">Hematologic:</span> Eosinophilia. <span class="typehead">Special Senses:</span> Tinnitus, nasal congestion, sneezing, diplopia. <span class="typehead">Skin:</span> Rash, purpura, erythema multiforme, exfoliative dermatitis, diaphoresis; petechiae, pruritus. <span class="typehead">Other:</span> Local reactions (phlebitis, thrombophlebitis (following IV), pain at injection sites), superinfections (gram-positive cocci),
      vaginal candidiasis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Aztreonam may cause transient elevations of <span class="alt">liver function tests,</span> increases in <span class="alt">PT</span> and <span class="alt">PTT,</span> minor changes in <span class="alt">Hgb,</span> and positive <span class="alt">Coombs' test.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Imipenem-cilastatin,</b>
<b>cefoxitin</b> may be antagonistic, <b>probenecid</b> slows renal elimination of aztreonam. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 1 h IM. <span class="typehead">Distribution:</span> Widely distributed including synovial and blister fluid, bile, bronchial secretions, prostate, bone, and CSF; crosses placenta;
      distributed into breast milk in small amounts. <span class="typehead">Metabolism:</span> Not extensively metabolized. <span class="typehead">Elimination:</span> 6070% excreted in urine within 24 h. <span class="typehead">Half-Life:</span> 1.62.1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline C&amp;S test prior to initiation of therapy. Start drug pending results.</li>
<li>Baseline and periodic renal function tests, particularly in older adults and in those with history of renal impairment.</li>
<li>Inspect IV injection sites daily for signs of inflammation. Pain and phlebitis occur in a significant number of patients.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Determine previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens prior to therapy.</li>
<li>Monitor for S&amp;S of opportunistic infections (diarrhea, rectal or vaginal itching or discharge, fever, cough) and promptly
            report onset to physician. Overgrowth of nonsusceptible organisms, particularly <i>staphylococci, streptococci,</i> and fungi, is a threat, especially in patients receiving prolonged or repeated therapy.
         </li>
<li>
            							Note: IV therapy may cause a change in taste sensation. Report interference with eating.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>